ROCKWELL MEDICAL, INC. (NASDAQ:RMTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ROCKWELL MEDICAL, INC. (NASDAQ:RMTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

Rockwell Medical, Inc.(the “Company”) hereby amends its Current Report on Form8‑K dated September5, 2017 and filed September11, 2017 (the “Original Form8‑K”) to provide information that was not determined or available at the time of the filing of theOriginal Form8‑K with respect to the appointment of JohnG. Cooper as a member of the Board of Directors of the Company (the “Board”). On September25, 2017, following a determination by the Board that Mr.Cooper qualifies as an “audit committee financial expert” as defined in the rules of the Securities and Exchange Commission (the “SEC”) and meets the independence requirements for audit committee members to the rules of the SEC and the Nasdaq Stock Market, Mr.Cooper was appointed to the Board’s Audit Committee to serve as its Chairman.


About ROCKWELL MEDICAL, INC. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

An ad to help with our costs